- :713-794-1220 :713-563-3166
Department of Hematopathology
MD Anderson Cancer Center
|07/1993 - 08/1997|| Residency, Oncology
Department of Oncology
Hubei Medical University (now Wuhan University School of Medicine) Wuhan, China
|01/2006 - 06/2010|| Postdoctoral Research Fellowship
Department of Medicine
University of Alabama at Birmingham
|07/2010 - 06/2014|| Residency, Anatomic and Clinical Pathology
Department of Pathology
University of Alabama at Birmingham
|07/2014 - present|| Clinical Fellowship, Hematopathology
Department of Pathology
Brigham and Women’s Hospital
Harvard Medical School
Dr. Jie Xu has received her MD from Hubei Medical University and her PhD from the University of Alabama at Birmingham. She is currently an assistant professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center. She is board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, and Hematology. Dr. Xu has been actively participating in multiple research projects in tumors of hematopoietic and lymphoid tissue, and cancer, which has led to 25 research papers, 20 presentations at the national and international conferences, and multiple awards. Her major research interests include diagnostic and prognostic factors in lymphoma and leukemia, and the potential therapeutic targets for hematopoietic neoplasms.
Diagnostic and prognostic factors in lymphoma and leukemia.
Potential therapeutic targets for hematopoietic neoplasms.
Honors And Awards
|2014||Roger Denio Baker Prize in Anatomical Pathology, Department of Pathology, University of Alabama at Birmingham|
|2014||Pappy Award in Cytopathology, Department of Pathology, University of Alabama at Birmingham|
|2013||The First Place, Top Five Junior Member Abstracts Award, College of Pathologist’s Annual Meeting|
|2013||Paper for the Month of January 2013, Department of Medicine, University of Alabama at Birmingham|
|2012||Award for Recognition of Outstanding Research, Department of Pathology, University of Alabama at Birmingham|
|2011||Adams Research Grant Award, Department of Pathology, University of Alabama at Birmingham|
- Xu J, Sun H, Morgan EA, Pinkus GS, Hornick JL, Fletcher CDM, Freeman GJ, and Rodig SJ. Expression of the Immunosuppressive Molecules PD-L1 and PD-L2 by Histiocytic and Dendritic Cell Neoplasms: Novel Candidates for PD-1 Pathway Immunotherapy (in revision, American Journal of Surgical Pathology).
- Isayeva T, Xu J, Ragin C, Dai Q, Cooper T, Carroll W, Dayan D, Vered M, Wenig B, Rosenthal E, Grizzle W, Anderson J, Willey CD, Yang ES, Brandwein-Gensler M. The Protective Effect of p15Ink4A in Oral Cavity Carcinomas: p16Ink4A Dampens Tumor Invasion, Integrated Analysis of Expression and Kinomic Pathways. Modern Pathology 2014 Dec 19. Doi: 10.1038/modpathol.2014. 149. [Epub ahead of print]. PMID: 25523612
- Xu J and Li S. Unusual T-lymphoblastic Blast Phase of Chronic Myelogenous Leukemia. Case Reports in Hematology 2014; 2014:304359. doi: 10.1155/2014/304359. Epub 2014 Jun 24. PMID: 25057418
- Xu J and Wei S. Breast Implant-Associated Breast Anaplastic Large Cell Lymphoma. Archives of Pathology & Laboratory Medicine 2014; 138:842-6. PMID: 24878027
- Isayeva T*, Xu J*, Dai Q, Whitley AC, Bonner J, Nabell L, Spencer S, Carroll W, , Jones G, Ragin C, Brandwein-Gensler M. African Americans with Oropharyngeal Carcinoma Have Significantly Poorer Outcomes Despite Similar Rates of HPV-Mediated Carcinogenesis. Human Pathology 2014; 45:310-9 (*cofirst authors). PMID: 24355195
- Xu J, Sun D, Jiang J, Deng L, Zhang Y, Yu H, Bahl D, Langenheim JF, Chen WY, Fuchs, SY, Frank SJ. The Role of Prolactin Receptor in Growth Hormone Signaling in Breast Cancer Cells. Molecular Endocrinology 2013; 27:266-79. PMID: 23192981
- Xu J, Latif S, and Wei S. Metastatic Renal Cell Carcinoma Presenting as Gastric Polyps: a Case Report and Review of the Literature. International Journal of Surgery Case Reports 2012; 3:601-4. PMID: 22989776
- Jiang J, Wan Y, Wang X, Xu J, Harris JM, Lobie PE, Zhang Y, Zinn KR, Waters MJ, Frank SJ. Inhibitory GH Receptor Extracellular Domain Monoclonal Antibodies: Three-Dimensional Epitope Mapping. Endocrinology 2011; 152:4777-88. PMID: 21990310
- Xu J, Zhang Y, Jiang J, Lobie P, Chen WY, and Frank SJ. Growth Hormone Signaling in Human T47D Breast Cancer Cells: Potential Role for a Growth Hormone Receptor-Prolactin Receptor Complex. Molecular Endocrinology 2011; 25:597-610. PMID: 21310852
- Xu J and Messina JL. Crosstalk between Growth Hormone and Insulin Signaling. Vitamins and Hormones. 2009; 80:125-53 (Review). PMID: 19251037
- Xu J, Kim HT, Ma Y, Zhao L, Zhai L, Kokorina N, Wang P, Messina JL. Trauma and Hemorrhage-Induced Acute Hepatic Insulin Resistance: Dominant Role of Tumor Necrosis Factor-Alpha. Endocrinology 2008; 149:2369-82. PMID: 18187553
- Bennet WL, Keeton AB, Ji S, Xu J, Messina JL. Insulin Regulation of Growth Hormone Receptor Gene Expression: Involvement of both the PI-3 Kinase and MEK/ERK Signaling Pathways. Endocrine 2007; 32:219-26. PMID: 18040895
- Fulzele K, DiGirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL. Disruption of the Insulin-Like Growth Factor Type 1 Receptor in Osteoblasts Enhances Insulin Signaling and Action. Journal of Biological Chemistry 2007; 282:25649-58. PMID: 17553792
- Xu J, Liu Z, Clemens TL, Messina JL. Insulin Reverses Growth Hormone-Induced Homologous Desensitization. Journal of Biological Chemistry 2006; 281:21594-606. PMID: 16717097
- Xu J, Keeton AB, Franklin JL, Li X, Venable DY, Frank SJ, Messina JL. Insulin Enhances Growth Hormone-Induction of the MEK/ERK Signaling Pathway. Journal of Biological Chemistry 2006; 281:982-92. PMID: 16272159
- Xu J, Keeton AB, Wu L, Franklin JL, Cao X, Messina JL. Gene 33 Inhibits Apoptosis of Breast Cancer Cells and Increases Poly (ADP-Ribose) Polymerase Expression. Breast Cancer Research and Treatment 2005; 91:207-15. PMID: 15952054
- Xu J, Ji S, Venable DY, Franklin JL, Messina JL. Prolonged Insulin Treatment Inhibits GH Signaling via STAT3 and STAT1. Journal of Endocrinology 2005; 184:481-92. PMID: 15749807
- Keeton AB, Xu J, Franklin JL, Messina JL. Regulation of Gene 33 Expression by Insulin Requires MEK-ERK Activation. Biochimica et Biophysica Acta 2004; 1679:248-55. PMID: 15358516
- Cheng J*, Xu J*, Zhou Y. Study of the Correlation between C-erbB-2 (HER2) Gene Amplification and MDR-1 Gene Expression in Breast Cancer Patients. Cancer Research on Prevention and Treatment (Chinese) 2002; 29:128-130 (*cofirst authors).
- Cheng J*, Xu J*, Zhou Y. C-erbB-2 (HER2) – Future Biological Marker for Breast Cancer Chemotherapy. Chinese Oncology 2002; 12:178-180 (Review) (*cofirst authors).
- Xu J and Zhou Y. C-erbB-2 (HER2) Oncogene and Breast Cancer. Chinese Clinical Oncology 2000; 5:146-148 (Review).
- Xu J, Cheng J, Zhou Y, Ge W. Analysis of the Prognosis of Patients with Regionally Recurrent Breast Cancer. Chinese Journal of Cancer 1998; 17:215-216.
- Deng D, Zhou Y, Xie C, Xu J. Postoperative Chest Wall Radiation Therapy in Patients with Advanced Breast Cancer. Journal of New Medicine (Chinese) 1998; 8:21-22.
- Cheng J, Ge W, Xu J, Zhou Y. Radiation Therapy for Pinealoma. Journal of New Medicine (Chinese) 1997; 7:164-165.
- Zhou Y, Xie C, Zhang J, Xu J. The Role of Radiation Therapy and Chemotherapy in Treating Colon Cancer. Journal of Clinical Surgery (Chinese) 1997; 5:109.